UAMY Q1 2026 Earnings Call Transcript

United States Antimony reported Q1 revenue of $6.8 million, roughly flat to down slightly year over year, but highlighted major operational and strategic progress: $60.2 million in cash at quarter-end, $48.6 million raised via equity, and a $27 million government grant with $12.8 million already received. Management reaffirmed 2026 revenue guidance of $125 million, with $75 million-$95 million expected from federal antimony ingot sales, while Thompson Falls expansion, the Idaho hydromet JV, and Fostung tungsten development all remain on track. The call emphasized growing government demand tied to defense and critical-mineral supply chains, though near-term earnings remain pressured by higher costs and a $4.1 million Larvotto mark-to-market loss.

Analysis

The market is starting to price UAMY less like a small-cap miner and more like a quasi-defense supplier with embedded project optionality. That re-rating can persist as long as grant dollars, DLA orders, and plant commissioning remain in sync, because each milestone reduces the perceived financing overhang and increases the probability of a multi-quarter order backlog. The second-order effect is that the company’s balance sheet is now strong enough to fund working capital without immediate dilution, which should mechanically support multiple expansion versus traditional resource names that still need equity every time they scale.

The real trade is not the reported quarter; it is the conversion of narrative into throughput over the next 60-120 days. If the new furnace line and feedstock logistics ramp on schedule, the equity can continue to trade on forward capacity rather than trailing revenue, which is why inventory buildup is more constructive than it would be in a normal mining name. But this also means the stock is highly sensitive to any commissioning slippage, permit friction, or government timing mismatch—one delayed milestone can rapidly compress the premium because the entire valuation is being underwritten by execution confidence.

The contrarian read is that the setup is crowded on the long side: management is explicitly marketing strategic relevance, and that tends to attract momentum capital before actual EBITDA arrives. That makes near-term upside asymmetric only if operational milestones hit cleanly; otherwise, the stock risks a classic “story stock” air pocket once investors realize federal funding does not equal free cash flow. The Larvotto mark-to-market issue is also a reminder that non-operating assets can still inject P&L noise and sentiment volatility even if the core business is improving.

Competitively, the beneficiaries are domestic processors and any upstream suppliers that can attach themselves to UAMY’s expanding platform; the losers are low-quality foreign feedstock sellers and legacy incumbents with slower permitting or weaker traceability. The broader macro implication is that UAMY is effectively monetizing geopolitical tension: more export restrictions and conflict headlines should support demand for domestic antimony stockpiling, but that same dynamic can also invite policy scrutiny if the equity keeps running ahead of actual domestic output. Over the next few months, the key question is whether the company can turn strategic scarcity into repeatable shipments rather than one-off contract optics.

Key Decisions for Investors

• Long UAMY into the next 4-8 weeks only on confirmed commissioning progress and DLA shipment follow-through; target is continued multiple expansion into the next catalyst, but cut quickly if furnace ramp slips or grant timing deteriorates.
• Buy UAMY call spreads expiring after the July commissioning window to express upside from milestone delivery while limiting downside from a schedule miss; this is a better risk/reward than common equity given execution volatility.
• Avoid chasing strength above recent highs unless volume expands with operational updates; the stock is likely to gap on headlines, but headline-only rallies are vulnerable to fast mean reversion if no new cash-flow evidence appears.
• Pair long UAMY / short a basket of non-revenue critical-mineral stories over the next 1-3 months to isolate execution alpha versus pure narrative beta; UAMY has real near-term catalysts, while many peers do not.
• Trim or hedge if the market begins capitalizing the full grant/contract backlog as immediate earnings power; that would be a sign the trade has become consensus and reward-to-risk has compressed sharply.